ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.47% | 9.88% | 16.97% | 13.14% | 8.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.47% | 9.88% | 16.97% | 13.14% | 8.42% |
| Cost of Revenue | 12.22% | 25.89% | 34.85% | 26.42% | 15.30% |
| Gross Profit | -0.45% | -3.33% | 2.86% | 3.10% | 3.02% |
| SG&A Expenses | 4.85% | 0.58% | 0.80% | -12.03% | -9.89% |
| Depreciation & Amortization | -33.27% | -35.01% | -33.71% | -3.18% | 22.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.50% | -7.16% | -18.12% | -23.17% | -22.66% |
| Operating Income | -0.33% | 26.46% | 46.68% | 51.72% | 47.04% |
| Income Before Tax | -76.68% | -34.30% | -1.08% | 41.77% | 35.77% |
| Income Tax Expenses | -102.61% | -85.07% | -56.14% | -1,127.38% | -3,412.03% |
| Earnings from Continuing Operations | -74.59% | -31.34% | 1.38% | 48.42% | 40.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.59% | -31.34% | 1.38% | 48.42% | 40.48% |
| EBIT | -0.33% | 26.46% | 46.68% | 51.72% | 47.04% |
| EBITDA | -25.52% | 24.66% | 54.32% | 62.73% | 61.66% |
| EPS Basic | -63.24% | -23.81% | 6.36% | 50.95% | 45.32% |
| Normalized Basic EPS | -1.74% | 26.36% | 47.21% | 53.87% | 49.92% |
| EPS Diluted | -63.24% | -23.81% | 6.36% | 50.95% | 45.32% |
| Normalized Diluted EPS | -1.74% | 26.36% | 47.21% | 53.87% | 49.92% |
| Average Basic Shares Outstanding | 7.63% | 4.73% | 2.97% | 5.89% | 11.44% |
| Average Diluted Shares Outstanding | 7.63% | 4.73% | 2.97% | 5.89% | 11.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
